- Home
- GF vs CLLS Comparison
GF vs CLLS Comparison
Compare GF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- CLLS
- Stock Information
- Founded
- GF 1990
- CLLS 1999
- Country
- GF Germany
- CLLS France
- Employees
- GF N/A
- CLLS N/A
- Industry
- GF Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- CLLS Health Care
- Exchange
- GF Nasdaq
- CLLS Nasdaq
- Market Cap
- GF 155.4M
- CLLS 144.4M
- IPO Year
- GF N/A
- CLLS 2007
- Fundamental
- Price
- GF $10.89
- CLLS $1.58
- Analyst Decision
- GF
- CLLS Buy
- Analyst Count
- GF 0
- CLLS 3
- Target Price
- GF N/A
- CLLS $6.67
- AVG Volume (30 Days)
- GF 28.1K
- CLLS 47.2K
- Earning Date
- GF 01-01-0001
- CLLS 05-12-2025
- Dividend Yield
- GF 0.82%
- CLLS N/A
- EPS Growth
- GF N/A
- CLLS N/A
- EPS
- GF N/A
- CLLS N/A
- Revenue
- GF N/A
- CLLS $54,748,000.00
- Revenue This Year
- GF N/A
- CLLS $48.52
- Revenue Next Year
- GF N/A
- CLLS $5.17
- P/E Ratio
- GF N/A
- CLLS N/A
- Revenue Growth
- GF N/A
- CLLS 351.27
- 52 Week Low
- GF $7.38
- CLLS $1.10
- 52 Week High
- GF $9.41
- CLLS $3.32
- Technical
- Relative Strength Index (RSI)
- GF 65.82
- CLLS 57.80
- Support Level
- GF $10.82
- CLLS $1.37
- Resistance Level
- GF $11.00
- CLLS $1.51
- Average True Range (ATR)
- GF 0.12
- CLLS 0.09
- MACD
- GF -0.01
- CLLS -0.01
- Stochastic Oscillator
- GF 84.29
- CLLS 75.00
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.